Beta Bionics (NASDAQ:BBNX) Rating Increased to Strong-Buy at UBS Group

Beta Bionics (NASDAQ:BBNX) was upgraded by equities research analysts at UBS Group to a “strong-buy” rating in a research note issued to investors on Monday,Zacks.com reports.

Other analysts have also issued reports about the company. The Goldman Sachs Group reissued a “buy” rating and issued a $25.00 price target on shares of Beta Bionics in a research note on Thursday, January 15th. Lake Street Capital increased their price objective on shares of Beta Bionics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Friday, January 9th. TD Cowen assumed coverage on shares of Beta Bionics in a report on Monday, January 26th. They issued a “hold” rating and a $17.00 target price for the company. Piper Sandler reaffirmed an “overweight” rating and set a $32.00 price target (up previously from $26.00) on shares of Beta Bionics in a research note on Wednesday, October 29th. Finally, Stifel Nicolaus decreased their price target on shares of Beta Bionics from $31.00 to $25.00 and set a “buy” rating on the stock in a report on Wednesday, February 4th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Beta Bionics has a consensus rating of “Moderate Buy” and an average price target of $26.42.

Beta Bionics Stock Up 6.6%

BBNX stock opened at $14.78 on Monday. Beta Bionics has a 52-week low of $8.89 and a 52-week high of $32.71. The stock’s fifty day simple moving average is $23.65 and its 200-day simple moving average is $22.66. The stock has a market capitalization of $650.76 million and a price-to-earnings ratio of -3.38.

Insider Buying and Selling at Beta Bionics

In related news, CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $29.53, for a total transaction of $590,600.00. Following the completion of the sale, the chief financial officer directly owned 42,614 shares of the company’s stock, valued at approximately $1,258,391.42. This represents a 31.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mike Mensinger sold 2,200 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $30.10, for a total value of $66,220.00. Following the completion of the transaction, the insider directly owned 80,752 shares in the company, valued at $2,430,635.20. This trade represents a 2.65% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 32,490 shares of company stock valued at $960,835 in the last three months.

Institutional Investors Weigh In On Beta Bionics

A number of large investors have recently modified their holdings of BBNX. TD Asset Management Inc raised its holdings in shares of Beta Bionics by 9.7% during the 4th quarter. TD Asset Management Inc now owns 65,876 shares of the company’s stock valued at $2,007,000 after buying an additional 5,800 shares during the period. Goldman Sachs Group Inc. grew its position in Beta Bionics by 1.5% in the fourth quarter. Goldman Sachs Group Inc. now owns 405,408 shares of the company’s stock valued at $12,353,000 after acquiring an additional 6,155 shares in the last quarter. BNP Paribas Financial Markets grew its position in Beta Bionics by 2,483.4% in the fourth quarter. BNP Paribas Financial Markets now owns 201,892 shares of the company’s stock valued at $6,152,000 after acquiring an additional 194,077 shares in the last quarter. Norges Bank purchased a new stake in shares of Beta Bionics during the fourth quarter valued at approximately $10,338,000. Finally, Intech Investment Management LLC acquired a new position in shares of Beta Bionics during the fourth quarter worth $393,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.